Erythropoietin Drug Market Is Projected To Grow Quickly Due To Patent Expiration Of Branded Drugs Till 2025: Grand View Research, Inc.
The
global erythropoietin (EPO) drugs market is expected to
reach USD 17.4 billion by 2025, according to a new report by Grand View
Research, Inc. Rising incidence of chronic diseases such as CKD and cancer
resulting in anemia is a major growth driver of this market.
According
to the statistics published by the National Heart, Lung, and Blood Institute of
the U.S. Department of Health & Human Services, over 3 million people are
affected by anemia every year and this number is expected to increase over the
forecast period. This showcases the need for erythropoietin-stimulating agents
in the coming years.
Introduction
of novel drugs and their cheaper biosimilar formulations with enhanced efficacy
and cost-effectiveness is also expected to serve this industry with lucrative
opportunities. For instance, development of numerous biosimilars in the
European market is expected to gain traction and increase their usage rates,
owing to associated benefits such as less time required for approval,
cost-efficiency, and enhanced therapeutic effect.
Companies
are involved in extensive R&D initiatives for development of innovative
molecules and discovering new therapeutic areas for existing drugs. For
instance, in April 2016, Sandoz received approval from the European Commission
for use of its biosimilar Binocrit in nephrology indications, thereby extending
the therapeutic area of its product portfolio.
Moreover,
many of the industry players in the U.S., Europe, and Asia Pacific are involved
in the development of new biosimilars. For example, Biocon’s subsidiary Syngene
International entered into an agreement with Bristol-Myers Squibb to extend
their drug discovery and development program in India. This enables Biocon to
enhance its erythropoietin drugs portfolio. Expected product approvals in the
coming years are anticipated to fuel market growth.
U.S. erythropoietin
drugs market revenue by drug class, 2014 - 2025 (USD billion)
Browse full
research report on Erythropoietin Drug Market: http://www.grandviewresearch.com/industry-analysis/erythropoietin-epo-drugs-market
Further
key findings from the report suggest:
- The
biologics segment is declining over the forecast period owing to patent
expiration of branded biologics and introduction of biosimilars in the
market
- The
patent for Aranesp (darbepoetin-alfa) will expire in 2024 in the U.S. and
is expected to provide numerous future growth opportunities for new market
entrants
- Epoetin-alfa
held the largest share of product segment owing to its early introduction
in the U.S. market and patent protection
- Epoetin-omega
and epoetin-zeta are anticipated to exhibit lucrative growth over the
forecast period owing to associated benefits such as longer half-life and
enhanced therapeutic effects
- Use of
erythropoietin drugs for treatment of renal diseases held a dominant share
as of 2016 owing to the increasing incidence of chronic kidney diseases
- The
Asia Pacific regional industry for erythropoietin-stimulating agents is
expected to witness lucrative CAGR during the forecast period
- Industry
participants are focusing on the discovery of new therapeutic areas for
existing drugs and development of cost-effective biosimilars, thereby
increasing R&D activities for the development of erythropoietin drugs.
Browse more
reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the erythropoietin (EPO) drugs market
on the basis of the drug class, product, application, and region:
Erythropoietin
Drugs Drug class Outlook (Revenue, USD Million, 2014 - 2025)
- Biologics
- Biosimilar
Erythropoietin
Drugs Product Outlook (Revenue, USD Million, 2014 - 2025)
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
Erythropoietin
Drugs Application Outlook (Revenue, USD Million, 2014 - 2025)
- Cancer
- Hematology
- Renal
Diseases
- Neurology
Erythropoietin
Drugs Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- Japan
- China
- India
- Latin
America
- Brazil
- Mexico
- MEA
- South
Africa
Access
Press Release By Grand View Research: http://www.grandviewresearch.com/press-release/global-erythropoietin-epo-drugs-market
About Grand
View Research:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Comments
Post a Comment